TriangleAdjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
Ovarian Cancer
ClinicalTrials.gov recordTREATMENT READING
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer, part 2
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
50 sections
- Follow-Up After Treatment
- Treatment Option Overview for Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer
- Capecitabine and Fluorouracil Dosing
- Treatment of Low-Grade Serous Carcinoma
- Treatment Options for Low-Grade Serous Carcinoma
- Surgery with or without chemotherapy
- Secondary cytoreductive surgery
- Targeted therapies
- Treatment of Early-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer
- Treatment Options for Early-Stage Ovarian Epithelial Cancer, FTC, and PPC
- Surgery with or without chemotherapy
- Treatment of Advanced-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer
- Treatment Options for Advanced-Stage Ovarian Epithelial Cancer, FTC, and PPC
- Surgery followed by platinum-based chemotherapy
- Surgery before or after platinum-based chemotherapy and/or additional consolidation therapy
- Surgery before or after platinum-based chemotherapy and the addition of bevacizumab to induction and/or consolidation therapy
- Surgery after platinum-based chemotherapy and the addition of HIPEC
- Surgery before or after platinum-based chemotherapy and the addition of poly (ADP-ribose) polymerase (PARP) inhibitors to induction and/or consolidation therapy
- Other consolidation and/or maintenance therapy trials
- Treatment options under clinical evaluation
- Treatment of Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer
- Treatment Options for Patients with Recurrent or Persistent Ovarian Epithelial Cancer, FTC, and PPC
- Platinum-sensitive recurrence
- Platinum-containing chemotherapy regimens
- Bevacizumab, other targeted drugs, and poly (ADP-ribose) polymerase (PARP) inhibitors with or without chemotherapy
- Platinum-refractory or platinum-resistant recurrence
- Chemotherapy
- Chemotherapy and/or bevacizumab
- Immune checkpoint inhibitors
- Antibody-drug conjugates
- Ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer form in the same type of tissue and are treated the same way.
- Certain factors affect treatment options and prognosis (chance of recovery).
- Ovarian epithelial, fallopian tube, and primary peritoneal cancers are grouped for treatment as early or advanced cancer.
- Ovarian epithelial, fallopian tube, and primary peritoneal cancers can recur (come back) after treatment.
- Treatment Option Overview
- Key Points
- There are different types of treatment for patients with ovarian epithelial cancer.
- The following types of treatment are used:
- Surgery
- Chemotherapy
- Targeted therapy
- New types of treatment are being tested in clinical trials.
- Radiation therapy
- Immunotherapy
- Treatment for ovarian epithelial, fallopian tube, and primary peritoneal cancers may cause side effects.
- Patients may want to think about taking part in a clinical trial.
- Follow-up care may be needed.
- Treatment of Early Ovarian Epithelial and Fallopian Tube Cancers
- Treatment of Advanced Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers
- Treatment of Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers
Treatment for ovarian epithelial, fallopian tube, and primary peritoneal cancers may cause side effects.
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Patients may want to think about taking part in a clinical trial.
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Follow-up care may be needed.
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Treatment of Early Ovarian Epithelial and Fallopian Tube Cancers
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of early ovarian epithelial cancer or fallopian tube cancer may include:
Sources: ovarian epithelial cancer · fallopian tube cancer
Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Lymph nodes and other tissues in the pelvis and abdomen are removed and checked under a microscope for cancer cells. Chemotherapy may be given after surgery.
Sources: Hysterectomy · bilateral salpingo-oophorectomy · omentectomy · Lymph nodes · tissues · pelvis · abdomen · Chemotherapy
Unilateral salpingo-oophorectomy may be done in certain women who wish to have children. Chemotherapy may be given after surgery.
Sources: Unilateral salpingo-oophorectomy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Treatment of Advanced Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer may include:
Sources: ovarian epithelial cancer · fallopian tube cancer · primary peritoneal cancer
Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Lymph nodes and other tissues in the pelvis and abdomen are removed and checked under a microscope to look for cancer cells. Surgery is followed by one of the following:
Sources: Hysterectomy · bilateral salpingo-oophorectomy · omentectomy · Lymph nodes · tissues · pelvis · abdomen
Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Lymph nodes and other tissues in the pelvis and abdomen are removed and checked under a microscope to look for cancer cells. Surgery is followed by one of the following:
Intravenous chemotherapy.
Sources: Intravenous chemotherapy
Intraperitoneal chemotherapy.
Sources: Intraperitoneal chemotherapy
Chemotherapy and targeted therapy (bevacizumab).
Sources: Chemotherapy · targeted therapy · bevacizumab
Chemotherapy and targeted therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor.
Chemotherapy and targeted therapy followed by surgery (possibly followed by intraperitoneal chemotherapy).
Chemotherapy and hyperthermic peritoneal chemotherapy (HIPEC) followed by surgery.
Chemotherapy alone for patients who cannot have surgery.
Targeted therapy with a PARP inhibitor (olaparib, rucaparib, niraparib).
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Treatment of Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer may include:
Sources: recurrent · ovarian epithelial cancer · fallopian tube cancer · primary peritoneal cancer
Chemotherapy using one or more anticancer drugs.
Sources: Chemotherapy
Targeted therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib, rucaparib, or niraparib) with or without chemotherapy.
Sources: Targeted therapy · poly (ADP-ribose) polymerase (PARP) inhibitor · olaparib · rucaparib · niraparib
Chemotherapy and/or targeted therapy (bevacizumab).
Sources: bevacizumab
A clinical trial of hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery.
Sources: clinical trial · hyperthermic intraperitoneal chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Studies
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
Ovarian Cancer, Primary Peritoneal Cavity Cancer
ClinicalTrials.gov recordEarly Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
ClinicalTrials.gov recordCombination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
Ovarian Cancer, Primary Peritoneal Cavity Cancer
ClinicalTrials.gov recordChemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
ClinicalTrials.gov recordCombination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
ClinicalTrials.gov recordBevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
ClinicalTrials.gov recordBevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
ClinicalTrials.gov recordTrial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
ClinicalTrials.gov recordCarboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian...
ClinicalTrials.gov recordSecondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordA Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Ovarian Cancer
ClinicalTrials.gov recordCarboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
ClinicalTrials.gov recordCarboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous...
ClinicalTrials.gov recordDose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Ovarian Neoplasms
ClinicalTrials.gov recordStudy Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordAURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordStudy Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
ClinicalTrials.gov recordPaclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell...
ClinicalTrials.gov recordFirst-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Tumors
ClinicalTrials.gov recordSurgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
ClinicalTrials.gov recordICON8: Weekly Chemotherapy in Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordBevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Recurrent Ovarian Cancer
ClinicalTrials.gov recordOlaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
ClinicalTrials.gov recordA Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
ClinicalTrials.gov recordA Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
ClinicalTrials.gov recordOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
ClinicalTrials.gov recordA Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
ClinicalTrials.gov recordPhase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
ClinicalTrials.gov recordA Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Ovarian Neoplasms, Ovarian Cancer
ClinicalTrials.gov recordPhase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordVeliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer, Ovarian Neoplasm
ClinicalTrials.gov recordPlatine, Avastin and OLAparib in 1st Line
Ovarian Cancer
ClinicalTrials.gov recordA Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
Ovarian Cancer
ClinicalTrials.gov recordA Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
ClinicalTrials.gov recordA Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Ovarian Neoplasms
ClinicalTrials.gov recordNiraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer,...
ClinicalTrials.gov recordAvelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
Ovarian Cancer
ClinicalTrials.gov recordARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
ClinicalTrials.gov recordA Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
ClinicalTrials.gov recordOTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Ovarian Cancer
ClinicalTrials.gov recordRibociclib and Letrozole Treatment in Ovarian Cancer
Low Grade Serous Carcinoma
ClinicalTrials.gov recordLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC...
ClinicalTrials.gov recordA Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
ClinicalTrials.gov recordA Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
ClinicalTrials.gov recordA Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
ClinicalTrials.gov recordPembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
ClinicalTrials.gov recordRelacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
ClinicalTrials.gov recordTreatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
ClinicalTrials.gov recordBelinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma, Stage III Borderline Ovarian...
ClinicalTrials.gov recordFondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
ClinicalTrials.gov recordZiv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian...
ClinicalTrials.gov recordLetrozole in Patients With Ovarian Tumors
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
ClinicalTrials.gov recordSelumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Low Grade Serous...
ClinicalTrials.gov recordAllogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
ClinicalTrials.gov recordOutcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
ClinicalTrials.gov recordPaclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I...
ClinicalTrials.gov recordTemsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid...
ClinicalTrials.gov recordStereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent...
ClinicalTrials.gov recordCarboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6...
ClinicalTrials.gov recordTrametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous...
ClinicalTrials.gov recordMetformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma,...
ClinicalTrials.gov recordTORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma,...
ClinicalTrials.gov recordGene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial...
ClinicalTrials.gov recordCAR T Cells in Mesothelin Expressing Cancers
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum
ClinicalTrials.gov recordA Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
ClinicalTrials.gov recordTrial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
ClinicalTrials.gov recordDisease and treatment settings
ALYMSYS: recurrent peritoneal cancer
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Alymsys, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent...
Avastin: peritoneal cancer after prior therapy
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV...
Avastin: recurrent peritoneal cancer
Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian,...
Elahere: peritoneal cancer after prior therapy
Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy...
Fallopian Tube Neoplasm
Fallopian Tube Neoplasm
JOBEVNE: peritoneal cancer after prior therapy
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Jobevne, in combination with carboplatin and paclitaxel, followed by Jobevne as a single agent, is indicated for the treatment of patients with stage III or IV...
JOBEVNE: recurrent peritoneal cancer
Jobevne, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Jobevne as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian,...
KEYTRUDA QLEX: Primary Peritoneal Carcinoma with PD-L1 stated without a specific alteration after prior therapy
( 1.18 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma...
KEYTRUDA: Primary Peritoneal Carcinoma with PD-L1 stated without a specific alteration after prior therapy
1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma...
Lifyorli: peritoneal cancer after prior therapy
LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to...
Lynparza: advanced peritoneal cancer (first-line)
1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial...
Lynparza: advanced peritoneal cancer with BRCA stated without a specific alteration (first-line)
• for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial...
Lynparza: recurrent peritoneal cancer with BRCA stated without a specific alteration (maintenance)
1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial...
Malignant Fallopian Tube Neoplasm
Malignant Fallopian Tube Neoplasm
MVASI: peritoneal cancer after prior therapy
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer MVASI, in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, is indicated for the treatment of patients with stage III or IV epithelial...
MVASI: recurrent peritoneal cancer
MVASI, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by MVASI as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian...
Primary Peritoneal Carcinoma
Primary Peritoneal Carcinoma
Rubraca: recurrent peritoneal cancer with BRCA mutation (maintenance)
1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent...
Rubraca: recurrent peritoneal cancer with BRCA stated without a specific alteration, BRCA mutation (maintenance)
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian,...
Vegzelma: peritoneal cancer after prior therapy
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer VEGZELMA, in combination with carboplatin and paclitaxel, followed by VEGZELMA as a single agent, is indicated for the treatment of patients with stage III or IV...
Vegzelma: recurrent peritoneal cancer
VEGZELMA, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by VEGZELMA as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian,...
ZEJULA: advanced peritoneal cancer (first-line)
1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a...
ZEJULA: advanced peritoneal cancer with BRCA mutation (first-line)
• for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is...
ZEJULA: recurrent peritoneal cancer with BRCA stated without a specific alteration (maintenance)
1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent...
Zirabev: peritoneal cancer after prior therapy
1.6 Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ZIRABEV, in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, is indicated for the treatment of patients with stage III or IV...
Zirabev: recurrent peritoneal cancer
ZIRABEV, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who...
Drug labels
AVMAPKI FAKZYNJA CO-PACK
AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated...
DailyMed labelCytalux
1. INDICATIONS AND USAGE CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or...
DailyMed labelELAHERE
ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic...
DailyMed labelEthyol
ETHYOL is a cytoprotective agent indicated for: – reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. ( 1.1 ) – reduction of the incidence of moderate to...
DailyMed labelKYXATA
KYXATA is a platinum-based drug indicated in adults: As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. ( 1.1 ) As a single-agent for the treatment of ovarian carcinoma recurrent after prior...
DailyMed labelLifyorli
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...
DailyMed labelLynparza
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial...
DailyMed labelZEJULA
ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial...
DailyMed label